Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Cancers
•
Endometrial Cancer
•
NCI-CCC Tumor Board Question
•
NCI-CCC Gynecologic Tumor Board Question
•
University of Pennsylvania
What adjuvant therapy do you recommend for comprehensively staged, stage II, FIGO grade 3 deeply invasive endometrial cancer?
Answer from: at Community Practice
I would strongly consider external beam therapy and adjuvant chemotherapy.
Sign in or Register to read more
9480
Related Questions
How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
Would you consider trying Pembrolizumab + Lenvatinib after progression on first-line Carboplatin + Paclitaxel + Immunotherapy for metastatic endometrial cancer?
How do you manage a patient with widely metastatic serous endometrial cancer whose disease is stable after completion of 6 cycles of chemotherapy + immunotherapy?
If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?
Would you consider the addition of trabectedin to adjuvant doxorubicin in a patient with IVB leiomyosarcoma with completely resected disease (hysterectomy and thigh mass with negative margins)?
When do you consider adjuvant chemotherapy and/or RT for stage I-III high-grade uterine sarcomas s/p resection?
Following surgical staging, what adjuvant therapy would you recommend for stage IB grade 3 endometrioid endometrial carcinoma with +LVSI?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?